Ascentage Pharma Group International
AAPG31.730USD
-1.180-3.59%
Cierre 11/07, 16:00（ET）Cotizaciones retrasadas 15 min
0.00Cap. mercado
--P/E TTM
Más Datos de Ascentage Pharma Group International Compañía
Ascentage Pharma Group International is a holding company primarily engaged in discovering, developing and commercializing therapies primarily in hematological malignancies. The Company’s main business is engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus and certain age-related diseases. The Company’s main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918 and other products. The Company’s products are mainly used to address the major hematological malignancies, including chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and multiple myeloma. The Company mainly conducts its business in the domestic market.
Información de Ascentage Pharma Group International
Símbolo de cotizaciónAAPG
Nombre de la empresaAscentage Pharma Group International
Fecha de salida a bolsaOct 28, 2019
Director ejecutivoDr. Dajun Yang, M.D., Ph.D.
Número de empleados- -
Tipo de seguridadDepository Receipt
Fin del año fiscal- -
Dirección68 Xinqing Road, Suzhou Industrial Park
CiudadSUZHOU
Bolsa de valoresNASDAQ Global Market Consolidated
PaísChina
Código postal- -
Teléfono
Sitio Webhttps://www.ascentage.cn/
Símbolo de cotizaciónAAPG
Fecha de salida a bolsaOct 28, 2019
Director ejecutivoDr. Dajun Yang, M.D., Ph.D.
Ejecutivos de Ascentage Pharma Group International
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Raymond Jeffrey (Jeff) Kmetz
Mr. Raymond Jeffrey (Jeff) Kmetz
Chief Business Officer
Chief Business Officer
--
--
Mr. Thomas Joseph (Tom) Knapp, J.D.
Mr. Thomas Joseph (Tom) Knapp, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
,
,
Senior Vice President - Global Corporate Development and Finance
Senior Vice President - Global Corporate Development and Finance
--
--
Veet Misra
Veet Misra
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Yifan Zhai, M.D., Ph.D.
Dr. Yifan Zhai, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Wei Ren
Mr. Wei Ren
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Jin Cao
Mr. Jin Cao
Head - Finance
Head - Finance
--
--
Dr. Dazhong (Simon) Lu, Ph.D.
Dr. Dazhong (Simon) Lu, Ph.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. Dajun Yang, M.D., Ph.D.
Dr. Dajun Yang, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Raymond Jeffrey (Jeff) Kmetz
Mr. Raymond Jeffrey (Jeff) Kmetz
Chief Business Officer
Chief Business Officer
--
--
Mr. Thomas Joseph (Tom) Knapp, J.D.
Mr. Thomas Joseph (Tom) Knapp, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
,
,
Senior Vice President - Global Corporate Development and Finance
Senior Vice President - Global Corporate Development and Finance
--
--
Veet Misra
Veet Misra
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Yifan Zhai, M.D., Ph.D.
Dr. Yifan Zhai, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 3 de sep
Actualizado: mié., 3 de sep
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Point72 (DIFC) Ltd
0.02%
NEOS Investment Management, LLC
0.01%
Tema ETFS LLC
0.01%
HSBC Global Asset Management (UK) Limited
0.01%
Otro
99.94%
Accionistas
Accionistas
Proporción
Point72 (DIFC) Ltd
0.02%
NEOS Investment Management, LLC
0.01%
Tema ETFS LLC
0.01%
HSBC Global Asset Management (UK) Limited
0.01%
Otro
99.94%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
0.07%
Investment Advisor/Hedge Fund
0.01%
Otro
99.92%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
17
71.71K
0.08%
-198.02K
2025Q2
9
259.43K
0.28%
+259.43K
2025Q1
6
237.19K
0.27%
+237.19K
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Point72 (DIFC) Ltd
20.89K
0.02%
-4.51K
-17.77%
Jun 30, 2025
NEOS Investment Management, LLC
15.49K
0.02%
+15.49K
--
Jun 30, 2025
Tema ETFS LLC
15.49K
0.02%
+15.49K
--
Jun 30, 2025
HSBC Global Asset Management (UK) Limited
9.93K
0.01%
+9.93K
--
Jun 30, 2025
UBS Financial Services, Inc.
7.36K
0.01%
+4.88K
+196.89%
Jun 30, 2025
Chevy Chase Trust Company
5.75K
0.01%
+5.75K
--
Jun 30, 2025
XY Capital Ltd.
5.59K
0.01%
-17.91K
-76.22%
Jun 30, 2025
Morgan Stanley & Co. LLC
956.00
0%
+956.00
--
Jun 30, 2025
Geode Capital Management, L.L.C.
361.00
0%
--
--
Aug 31, 2025
Bell Investment Advisors, Inc.
67.00
0%
+67.00
--
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: jue., 6 de nov
Actualizado: jue., 6 de nov
Nombre
Proporción
Tema Oncology ETF
0.51%
Invesco Golden Dragon China ETF
0%
Tema Oncology ETF
Proporción0.51%
Invesco Golden Dragon China ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
